Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

Current Opinion in Immunology

Volumn 25, Issue 2, 2013, Pages 268-276

  Gajewski, Thomas F ^a   Woo, Seng Ryong ^a   Zha, Yuanyuan ^a   Spaapen, Robbert ^a   Zheng, Yan ^a   Corrales, Leticia ^a   Spranger, Stefani ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CANCER VACCINE; CHEMOKINE; DENILEUKIN DIFTITOX; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 7; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; DISEASE MARKER; GENE; HUMAN; IN VIVO STUDY; INFLAMMATION; LAG 3 GENE; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTATIC MELANOMA; NONHUMAN; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE; TIM 3 GENE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VALIDATION STUDY;

HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84877072174     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2013.02.009     Document Type: Review

References (97)

1. Peterson A.C., Harlin H., Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003, 21:2342-2348.
2. Fourcade J., Kudela P., Andrade Filho P.A., Janjic B., Land S.R., Sander C., Krieg A., Donnenberg A., Shen H., Kirkwood J.M., et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008, 31:781-791.
3. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., Cruz C.M., Angiulli A., Angiulli F., Ritter E., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181:776-784.
4. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. Nat Med 1998, 4:321-327.
5. Gajewski T.F., Meng Y., Harlin H. Chemokines expressed in melanoma metastases associated with T cell infiltration. J Clin Oncol 2007, 25:8501.
6. Gajewski T.F., Zha Y., Thurner B., Schuler G. Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol 2009, 27:9002.
7. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009, 69:3077-3085.
8. Louahed J., Gruselle O., Gaulis S., Coche T., Eggermont A.M., Kruit W., Dreno B., Charion Sileni V., Lehmann F., Brichard V.G. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol 2008, 26. (Abstract 9045).
9. Gajewski T.F., Louahed J., Brichard V.G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010, 16:399-403.
10. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., Guida M., Hyams D.M., Gomez H., Bastholt L., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204.
11. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., Alaparthy S., Berman D., Jure-Kunkel M., Siemers N.O., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011, 61:1019-1031.
12. Gajewski T.F. Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol 2011, 38:236-242.
13. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M.L., Ordonez G.R., Bignell G.R., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
14. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med 2011.
15. Fuertes M.B., Woo S.R., Burnett B., Fu Y.X., Gajewski T.F. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2012, 34:67-73.
16. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
17. Barber G.N. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr Opin Immunol 2011, 23:10-20.
18. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
19. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010, 11:997-1004.
20. Holm C.K., Jensen S.B., Jakobsen M.R., Cheshenko N., Horan K.A., Moeller H.B., Gonzalez-Dosal R., Rasmussen S.B., Christensen M.H., Yarovinsky T.O., et al. Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol 2012, 13:737-743.
21. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502.
22. Gall A., Treuting P., Elkon K.B., Loo Y.M., Gale M., Barber G.N., Stetson D.B. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36:120-131.
23. Ahn J., Gutman D., Saijo S., Barber G.N. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 2012, 109:19386-19391.
24. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13:332-333.
25. Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Forster I., Farlik M., Decker T., Du Pasquier R.A., Romero P., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.
26. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., Schietinger A., Philip M., Schreiber H., Fu Y.X. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004, 5:141-149.
27. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., Schreiber H., You Z., Kaynor C., Wang X., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 2007, 179:1960-1968.
28. Oh S.S., Moon C., Kim D.H., Song H., Park S., Fu Y., Kim K.D. Adenovirally delivered IFN-beta exerts antitumor effects through transient T-lymphocyte depletion and Ag-specific T-cell proliferation. Int J Mol Med 2012, 29:1153-1157.
29. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
30. Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., Katsaros D., O'Brien-Jenkins A., Gimotty P.A., Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36.
31. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011, 11:702-711.
32. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992, 175:139-146.
33. Zhang B., Zhang Y., Bowerman N.A., Schietinger A., Fu Y.X., Kranz D.M., Rowley D.A., Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008, 68:1563-1571.
34. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
35. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., Jove R., Yu H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999, 59:5059-5063.
36. Burdelya L., Kujawski M., Niu G., Zhong B., Wang T., Zhang S., Kortylewski M., Shain K., Kay H., Djeu J., et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005, 174:3925-3931.
37. Ugurel S., Schrama D., Keller G., Schadendorf D., Brocker E.B., Houben R., Zapatka M., Fink W., Kaufman H.L., Becker J.C. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008, 57:685-691.
38. Wu H.J., Ivanov I.I., Darce J., Hattori K., Shima T., Umesaki Y., Littman D.R., Benoist C., Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
39. Solana R., Tarazona R., Aiello A.E., Akbar A.N., Appay V., Beswick M., Bosch J.A., Campos C., Cantisan S., Cicin-Sain L., et al. CMV and immunosenescence: from basics to clinics. Immun Ageing 2012, 9:23.
40. Harlin H., Kuna T.V., Peterson A.C., Meng Y., Gajewski T.F. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006, 55:1185-1197.
41. Mortarini R., Piris A., Maurichi A., Molla A., Bersani I., Bono A., Bartoli C., Santinami M., Lombardo C., Ravagnani F., et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003, 63:2535-2545.
42. Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006, 177:1670-1678.
43. Gajewski T.F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007, 13:5256-5261.
44. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
45. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
46. Chapon M., Randriamampita C., Maubec E., Badoual C., Fouquet S., Wang S.F., Marinho E., Farhi D., Garcette M., Jacobelli S., et al. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol 2011, 131:1300-1307.
47. Mellor A.L., Sivakumar J., Chandler P., Smith K., Molina H., Mao D., Munn D.H. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001, 2:64-68.
48. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol Med 2004, 10:15-18.
49. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
50. Jandus C., Bioley G., Speiser D.E., Romero P. Selective accumulation of differentiated FOXP3(+) CD4(+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother 2008, 57:1795-1805.
51. Zheng Y., Zha Y., Driessens G., Locke F., Gajewski T.F. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 2012, 209:2157-2163.
52. Dong H., Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003, 81:281-287.
53. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
54. Zhang L., Gajewski T.F., Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009, 114:1545-1552.
55. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van Den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
56. Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
57. Litzinger M.T., Fernando R., Curiel T.J., Grosenbach D.W., Schlom J., Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007, 110:3192-3201.
58. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
59. Kline J., Brown I.E., Zha Y.Y., Blank C., Strickler J., Wouters H., Zhang L., Gajewski T.F. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res 2008, 14:3156-3167.
60. Chen L., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A., McGowan P., Linsley P.S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992, 71:1093-1102.
61. Townsend S.E., Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells [see comments]. Science 1993, 259:368-370.
62. Gajewski T.F., Fallarino F., Uyttenhove C., Boon T. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 1996, 156:2909-2917.
63. Fallarino F., Ashikari A., Boon T., Gajewski T.F. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol 1997, 9:1259-1269.
64. Boussiotis V.A., Barber D.L., Nakarai T., Freeman G.J., Gribben J.G., Bernstein G.M., D'Andrea A.D., Ritz J., Nadler L.M. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994, 266:1039-1042.
65. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., Dhanji S., Nguyen L.T., Gronski M.A., Morre M., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009, 15:528-536.
66. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004, 101:1969-1974.
67. Epardaud M., Elpek K.G., Rubinstein M.P., Yonekura A.R., Bellemare-Pelletier A., Bronson R., Hamerman J.A., Goldrath A.W., Turley S.J. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008, 68:2972-2983.
68. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005, 202:907-912.
69. Wang L.X., Li R., Yang G., Lim M., O'Hara A., Chu Y., Fox B.A., Restifo N.P., Urba W.J., Hu H.M. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res 2005, 65:10569-10577.
70. Brown I.E., Blank C., Kline J., Kacha A.K., Gajewski T.F. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol 2006, 177:4521-4529.
71. Kline J., Zhang L., Battaglia L., Cohen K.S., Gajewski T.F. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012, 188:2630-2642.
72. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
73. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2443-2465.
74. Kuzel T.M. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date. Clin Lymphoma 2000, 1(Suppl. 1):S33-S36.
75. Rasku M.A., Clem A.L., Telang S., Taft B., Gettings K., Gragg H., Cramer D., Lear S.C., McMasters K.M., Miller D.M., et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6:12.
76. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., Clay T.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
77. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633.
78. Attia P., Maker A.V., Haworth L.R., Rogers-Freezer L., Rosenberg S.A. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005, 28:582-592.
79. Rech A.J., Mick R., Martin S., Recio A., Aqui N.A., Powell D.J., Colligon T.A., Trosko J.A., Leinbach L.I., Pletcher C.H., et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012, 4:134ra162.
80. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., Brown M.R., Fleisher T.A., Noel P., Maric I., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735.
81. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
82. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012, 33:35-41.
83. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., Sievers E.L., Hughes S.D., DeVries T.A., Hausman D.F. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008, 26:2034-2039.
84. Petrella T.M., Tozer R., Belanger K., Savage K.J., Wong R., Smylie M., Kamel-Reid S., Tron V., Chen B.E., Hunder N.N., et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012, 30:3396-3401.
85. Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14639-14645.
86. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
87. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392.
88. Matsuzaki J., Gnjatic S., Mhawech-Fauceglia P., Beck A., Miller A., Tsuji T., Eppolito C., Qian F., Lele S., Shrikant P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010, 107:7875-7880.
89. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
90. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
91. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
92. Wang S., Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Curr Top Microbiol Immunol 2011, 344:245-267.
93. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., Karanes C., Theobald M., Bennett J.M., Sherman M.L., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244-3254.
94. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Dieras V., Guardino E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
95. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
96. Galon J., Pages F., Marincola F.M., Thurin M., Trinchieri G., Fox B.A., Gajewski T.F., Ascierto P.A. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1.
97. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010.